Comparative study of 2 different Radiotherapy Schedules in Glioblastoma Multiforme patients

Hypofractionated accelerated Radiotherapy versus Conventional Radiotherapy in Glioblastoma Multiforme: A prospective randomised controlled study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/079080

Enrollment

Registered

2025-01-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C718- Malignant neoplasm of overlappingsites of brain

Interventions

Intervention1: Hypofractionated accelerated chemo radiation , adjuvant chemotherapy: 52.5 Grey delivered in 15 fractions, once daily over 19 days with concurrent Temozolomide @ 75 mg/m2 once daily and

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically proven patients of Glioblastoma Multiforme 2. Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-2 3. Patients willing to give written consent for the study.

Exclusion criteria

Exclusion criteria: 1. Recurrent cases of Glioblastoma Multiforme, previously treated. 2. Patients with any contraindications to Radiotherapy

Design outcomes

Primary

Measure	Time frame
Loco regional controlTimepoint: 2 years	—

Secondary

Measure	Time frame
Overall Survival Progression free survival Quality of LifeTimepoint: 2 years	—

Countries

India

Contacts

Public ContactDipanjan Nandi

Department of Radiotherapy and Radiation Medicine, Institute of Medical Sciences, BHU, Varanasi

drsunil104@gmail.com9559481453

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026